Media & Resources

First Clinical Study of Electroporation-Enhanced DNA Vaccine Delivery in Healthy Human Volunteers NEW YORK, NY, and SAN DIEGO, CA, November 30, 2009 – A Phase I study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines…

Publication to Serve as Guide to Understanding, Building Productive Partnerships November 20, 2009 – Washington, DC – Meaningful and lasting progress in addressing global health challenges cannot be achieved without partnerships and collaboration, according to a publication released today, Case Studies for Global Health. The collection of case studies, which focus on access to medicines…

IAVI commends the Obama Administration for lifting the ban on people living with HIV from entering the United States. The process of reversing this policy was initiated by President George W. Bush and received Congressional support when PEPFAR was reauthorized last year. AIDS is a global epidemic, and the mobilization to combat the epidemic is…

Data Unveiled at Leading Scientific Conference Shows Promising Advances on Several Fronts The annual AIDS Vaccine 2009 conference, held in Paris from October 19-22, brought together more than 1,000 scientists from across the world engaged in an exciting new phase of AIDS vaccine research and development.  “There are many reasons for hope,” Michel Sidibé, executive…

The International AIDS Vaccine Initiative and the Ragon Institute Signed Memorandum of Understanding to Collaborate on AIDS Vaccine Research NEW YORK, October 16, 2009 ─The International AIDS Vaccine Initiative (IAVI) announced today that it has signed a memorandum of understanding with the Ragon Institute to accelerate the development of new and promising AIDS vaccine candidates…

NEW YORK, NY, SEPTEMBER 24, 2009 –The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS vaccine candidates has shown partial efficacy in a phase III efficacy trial…

LA JOLLA, CA and NEW YORK, NY September 24, 2009 – Today, the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute officially launched a new research center, the IAVI Neutralizing Antibody Center at The Scripps Research Institute.  Scientists at the Neutralizing Antibody Center will focus on designing AIDS vaccines that elicit antibodies that…

Findings Reveal an Achilles Heel on the Virus for AIDS Vaccine Researchers to Exploit  NEW YORK, NY, LA JOLLA and SAN FRANCISCO, CA, SEATTLE, WA, September 3, 2009—Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered…